AKBA News and Press, Akebia Therapeutics Inc. From 05/09/24

2024-05-09 07:21:26 ET More on Akebia Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade) Akebia Q1 2024 Earnings Preview Akebia stock jumps as FDA clears renal anemia ...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-05-08 11:42:17 ET More on Akebia Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade) Akebia stock jumps as FDA clears renal anemia therapy Akebia GAAP EPS of $0.00...

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights PR Newswire Akebia to Host Conference Call on May 9, 2024 , at 8:00 a.m. ET CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- Akebia Therapeutics ...

2024-04-04 17:56:46 ET Summary Akebia Therapeutics, Inc.'s drug Vadadustat, known as Vafseo, received FDA approval for the treatment of anemia in adults on dialysis, offering improved anemia management for a large patient population. The company's other FDA-approved drug, Auryxia,...

2024-04-02 06:16:12 ET Summary Akebia's Vafseo, a HIF-PH inhibitor for DD-CKD anemia, faces skepticism despite FDA approval due to safety concerns. Market skepticism towards HIF-PH inhibitors, evidenced by GSK's hesitance in Europe, suggests limited adoption for Vafseo. Akebia...

2024-03-28 14:00:02 ET Ed Arce from H.C. Wainwright issued a price target of $6.00 for AKBA on 2024-03-28 12:08:00. The adjusted price target was set to $6.00. At the time of the announcement, AKBA was trading at $1.98. The overall price target consensus is at $7.00 with...

2024-03-28 13:30:02 ET H.C. Wainwright analyst issues BUY recommendation for AKBA on March 28, 2024 12:08PM ET. The previous analyst recommendation was Buy. AKBA was trading at $2.0093 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...

Akebia Therapeutics, Inc. (NASDAQ: AKBA) is one today's most active stocks by volume. So far today, approximately 31.95M shares of Akebia Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 4.98M shares. Akebia Therapeutics, Inc., a biopharmaceutical company, foc...

A look at the top 10 most actives in the United States Akanda Corp. (AKAN) rose 54.8% to $0.2552 on volume of 35,107,796 shares Nikola Corporation (NKLA) rose 5.0% to $0.9546 on volume of 25,515,019 shares Biodexa Pharmaceuticals plc (BDRX) rose 83.9% to $1.58 on volume of 24,185,655 shar...